Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis
Authors:
- 12 January 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 57 (4) , 656-660
Abstract
ABCG2 rs2231142 (Q141K) has been reported to be associated with poor response to allopurinol, while there are conflicting data on the association between the genetically independent ABCG2 rs10011796 variant and allopurinol response. The aim of this study was to replicate the association of ABCG2 rs2231142 and rs10011796 with allopurinol response and perform a meta-analysis. Participants in the Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO) (n = 299) were studied. In patients with evidence of adherence to allopurinol therapy (plasma oxypurinol >20 μmol/l), good response was defined as serum urate 300 mg/day. Association of rs2231142 and rs10011796 with poor response was tested in logistic regression models that included age, sex, BMI, ethnicity and estimated glomerular filtration rate. Results from the LASSO study and a subset of participants in the Genetics of Gout in Aotearoa New Zealand study (n = 296, including 264 from a previously published report) were combined by meta-analysis. There was evidence for association of rs2231142 with allopurinol response [odds ratio (OR) = 2.35, P = 7.3 × 10−4] but not for rs10011796 (OR = 1.21, P = 0.33) in the LASSO cohort using an adjusted logistic regression model. Meta-analysis provided evidence of a significant association of rs2231142 with allopurinol response (OR = 2.43, P = 6.2 × 10−7), but not rs10011796 (OR = 1.06, P = 0.69). This study has confirmed the significant association of ABCG2 rs2231142 with poor response to allopurinol.Keywords
This publication has 17 references indexed in Scilit:
- ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approachesPharmacogenomics and Personalized Medicine, 2017
- 2016 updated EULAR evidence-based recommendations for the management of goutAnnals of the Rheumatic Diseases, 2017
- ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with goutThe Pharmacogenomics Journal, 2016
- An open-label, 6-month study of allopurinol safety in gout: The LASSO studySeminars in Arthritis and Rheumatism, 2015
- Genome‐wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug responseClinical Pharmacology & Therapeutics, 2015
- Illumina human exome genotyping array clustering and quality controlNature Protocols, 2014
- Genome-wide association analyses identify 18 new loci associated with serum urate concentrationsNature Genetics, 2012
- 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaArthritis Care & Research, 2012
- Identification of a urate transporter, ABCG2, with a common functional polymorphism causing goutProceedings of the National Academy of Sciences, 2009
- Preliminary criteria for the classification of the acute arthritis of primary goutArthritis & Rheumatism, 1977